Mr. Todd Shapiro reports

RED LIGHT HOLLAND TO SUPPORT UNIVERSITY OF CALIFORNIA SAN FRANCISCO'S GLOBAL PSYCHEDELIC STUDY THROUGH FILAMENT HEALTH'S CLINICAL NETWORK

Through Filament Health Corp., Red Light Holland Corp. will support the Carhart-Harris Lab at the University of California, San Francisco, by providing instructions on how to participate in the CHL global psychedelic study to all researchers and clinicians receiving PEX010, including clinical trials and compassionate use programs.

Filament is a leading supplier of pharmaceutical-grade botanical psilocybin. Its patented drug candidate, PEX010, has been supplied to over 70 trials worldwide and has been authorized for use in several federally authorized compassionate use programs.

The CHL global psychedelic study is a large-scale on-line research initiative led by Dr. Robin Carhart-Harris, the Ralph Metzner distinguished professor of neurology, psychiatry and behavioural sciences at UCSF. The study examines a broad range of factors shaping individual responses to psychedelics in naturalistic settings and is open to anyone planning to take a psychedelic substance in any type of setting.

"Filament's wide distribution of PEX010 offers a unique opportunity for this study to gain access to a wider patient population," said Todd Shapiro, chief executive officer and director of Red Light Holland. "We are excited to help contribute real-world evidence to the global scientific understanding of botanical psilocybin, in the hope of informing both policy-makers and the medical community as we work toward increasing legal, responsible accessibility for patients who could benefit."

"The more diverse and representative our data, the stronger the science," said Dr. Carhart-Harris, Ralph Metzner distinguished professor of neurology, psychiatry and behavioural sciences at UCSF. "Patients receiving legal access to psilocybin, especially under compassionate use, represent an important and understudied population. Their participation will help us build a clearer picture of how psychedelics work across different clinical and real-world contexts."

About Red Light Holland Corp.

Red Light Holland is an Ontario-based organization advancing a focused strategy within the legal psychedelic sector, centred on consensual data collection and research and development initiatives designed to expand naturally occurring drug development, understanding of psilocybin use and consumer experiences. In parallel, the company operates commercial activities across Europe and North America, including psilocybin truffle sales in the Dutch legal market and mushroom home grow kits offered through business-to-business and direct-to-consumer channels, in compliance with applicable laws.

We seek Safe Harbor.